Report cover image

Europe Allogeneic Human Chondrocyte Market, By Application (Osteoarthritis, Musculoskeletal System Disorders, and Others), By End User (Hospitals, Specialty Clinics, and Ambulatory Surgical Centers), and By Country (Germany, U.K., France, Italy, Spain, Ru

Publisher Coherent Market Insights
Published May 02, 2022
Length 107 Pages
SKU # CMI17212481

Description

Europe Allogeneic Human Chondrocyte Market, By Application (Osteoarthritis, Musculoskeletal System Disorders, and Others), By End User (Hospitals, Specialty Clinics, and Ambulatory Surgical Centers), and By Country (Germany, U.K., France, Italy, Spain, Russia, and Rest of Europe) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Allogeneic human chondrocyte cell therapy is anticipated to be a good alternative to autologous chondrocyte implantation in the near future. Increasing product approvals by regulatory authorities is expected to fuel the market growth over the forecast period. For instance, in July 2017, Kolon TissueGene, Inc. received the South Korea Ministry of Food & Drug Safety (MFDS) for Invossa-K Inj. The product is currently available in the South Korean market and is marketed by Mundipharma and Kolon Pharmaceuticals.
Market Dynamics
Most of the pharmaceutical manufacturers operating in the Europe allogeneic human chondrocyte market are engaged in adoption of inorganic growth strategies such as collaborations, partnerships, and agreements to strengthen their market presence and expand its geographical footprint. In June, Kolon TissueGene, Inc., a manufacturer and developer of advanced cell and gene therapies, announced the extension of license agreement with Kolon Life Science, Inc., for the sales of Invossa-K Inj, a cell and gene therapy for knee osteoarthritis. The agreement is expected to expand the geographical footprint of Kolon Life Science, Inc. in the Middle East region with the grant of license for Saudi Arabia and United Arab Emirates (UAE) by the year 2024.
Key features of the study:
This report provides in-depth analysis of the Europe allogeneic human chondrocyte market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Europe allogeneic human chondrocyte market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Kolon TissueGene, Inc. and ISTO Technologies Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, type up-gradation, market expansion, and marketing tactics
The Europe allogeneic human chondrocyte market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Europe allogeneic human chondrocyte market
Detailed Segmentation:
Europe Allogeneic Human Chondrocyte Market, By Application:
Osteoarthritis
Musculoskeletal System Disorders
Others
Europe Allogeneic Human Chondrocyte Market, By End User:
Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Europe Allogeneic Human Chondrocyte Market, By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Company Profiles
Kolon TissueGene, Inc.*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
ISTO Technologies Inc.
“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

107 Pages
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Application
Market Snippet, By End User
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Key Developments
PEST Analysis
4. Europe Allogeneic Human Chondrocyte Market – Impact of Coronavirus (Covid-19) Pandemic
Post COVID-19 Market Scenario
Clinical Trial Analysis
Demand Supply Impact
1. Europe Allogeneic Human Chondrocyte Market, By Application, 2017 - 2028, (US$ Mn)
Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 - 2028
Segment Trends
Osteoarthritis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Musculoskeletal System Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
2. Europe Allogeneic Human Chondrocyte Market, By End User, 2017 - 2028, (US$ Mn)
Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 - 2028
Segment Trends
Hospitals
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Specialty Clinics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Ambulatory Surgical Centers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
3. Europe Allogeneic Human Chondrocyte Market, By Country, 2017 - 2028, (US$ Mn)
Introduction
Market Share Analysis, By Country, 2022 and 2028 (%)
Y-o-Y Growth Analysis, For Country, 2017 - 2028
Germany
Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
U.K.
Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
France
Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
Italy
Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
Spain
Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
Russia
Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
Rest of Europe
Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
4. Competitive Landscape
Heat Map Analysis
Market Share Analysis
Kolon TissueGene, Inc.
Company Overview
Device Portfolio
Financial Overview
Key Highlights
Market Strategies
ISTO Technologies Inc.
Company Overview
Device Portfolio
Financial Overview
Key Highlights
Market Strategies
Analyst Views
5. Section
References
Research Methodology
About us and Sales Contact
*Browse 22 market data tables and 20 figures on “Allogeneic Human Chondrocyte Market” –Europe forecast to 2028

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us